Current Setup & Catalysts
Current Setup & Catalysts — Where the Story Sits and What Updates It
The setup, in one read
3099 is a +70% YTD melt-up into a guided-down forward year, on a name where management itself just told the market that FY3/2027 net income falls roughly 19% YoY [1]. The shares closed ¥3,871 on 19 June 2026 — 92% of the 52-week range (¥2,054–¥4,011), through the 200-day mean, RSI(14) at 71, +20.5% in the last month, +35.6% in the last three months, and through every published sell-side 12-month target except the StockAnalysis "high" outlier of ¥4,200. The market has spent the YTD pricing in (i) the Phase I 70%+ payout regime confirmed on 6 Feb 2026, (ii) the record FY3/2026 operating-profit print (¥80.0B / +4.8% YoY) delivered on 13 May 2026, and (iii) the second tranche of the Shinkong (Taiwan) equity-stake sale that closed 1 April 2026 with a disclosed transfer gain of approximately ¥10B [2]. What is not in the price is whether the kokyakugyō engine can hold the operating line at ¥80B+ as the Shinkong gain rolls off, the China-inbound layer normalises lower (¥3B sales / ¥0.5B profit hit already booked in Oct–Dec 2025 [3]), and the Phase I ¥85B FY3/2028 anchor is closed in the final year. This page is the bridge between that durable five-to-ten-year underwriting frame and the near-term evidence path that updates it — not a news digest, and explicitly not a verdict.
Variant view, sized in numbers. We sit above the FY3/2027 ¥81.5B operating-profit guide and aligned with the FY3/2028 ¥85B target — call it ¥83–84B for FY27 versus the company guide of ¥81.5B, on the basis that Hosoya has beaten his own first-pass guide by an average of ¥7B over the last three years (Story tab; FY25 ¥64B → ¥76.3B, FY26 ¥78B → ¥80B). We sit below the sell-side average ¥3,073 12-month target (-21% from spot) but reject CLSA's ¥2,100 underperform anchor (-46%) as priced for a cycle break that the kokyakugyō evidence base does not yet support. The single largest variant call is on FY3/2027 H1 (reported 12 Nov 2026): we expect identified-customer sales tracking +3-4% YoY against overseas/tax-free flat-to-down — i.e., the structural pillar absorbs the cyclical break. If we are wrong about that, the ¥85B Phase I anchor cracks and the stock unwinds to the JPMorgan ¥3,200 / Nomura ¥3,100 cluster. If we are right, the rally has further to run on the FY3/2028 print, not on the next two quarters.
Where we are vs. where the market sat six months ago
Last close (¥)
YTD return (%)
RSI(14)
vs consensus PT (%)
The shape of the YTD tape is decision-useful: the rally tracked specific catalysts, not a passive multiple expansion. The 6 Feb 2026 ¥30B / 18M-share buyback announcement (5.12% of float, running through 8 Feb 2027) sat the stock at ¥2,400 [4]; the CLSA "High Conviction Underperform" ¥2,100 note on 18 Mar 2026 made no dent (the tape was already through ¥3,000); the 1 April Shinkong-2 close carried the ~¥10B gain into Q1 FY3/2027 [2]; the 13 May FY3/2026 record print delivered a modest +3.5% same-week move because the ¥80B headline beat was already largely in the price. The implication is asymmetric for the next 90 days: the market has consumed the easy good news, so the next two prints (Q1 FY3/2027 on 13 Aug 2026; H1 on 12 Nov 2026) get the burden of justifying the rerate against a guided-down FY27 number.
What changed in the last 3–6 months
This is the recent setup the page bridges from — captured below as the data points a PM needs in front of them when they pull the tab. Every entry below the last six months is sourced upstream; we cite to the corpus only when we introduce a raw filing fact that the upstream did not.
The recent narrative arc has moved in three steps. Six months ago the live debate was "is the dividend/buyback policy real?" — answered yes on 6 Feb 2026 with the ¥30B / 18M / 70%-payout package. Three months ago the debate became "can the FY3/2026 operating-profit print clear ¥80B?" — answered yes on 13 May at ¥80.0B. Today the debate is "does the kokyakugyō engine absorb the inbound break and the Shinkong roll-off into FY3/2028?" That is the question every catalyst inside the next six months is testing.
How the stock actually trades a print — historical base rate
Magnitude claims below are anchored in this base rate, not in vibes. The data is from the staged earnings calendar (yfinance:3099.T) and the daily price tape; rows show the prior-close price, the next-day move, and the 5-trading-day move from prior close.
Three reads matter for sizing forward catalysts:
- Average absolute +1d move on the last 8 prints is ~4.2%; average absolute +5d move is ~6.4%. The single largest five-day move was post the 13 May 2024 FY24 print (+24.2%) and the 12 May 2025 FY25 print (+14.7%) — both new-plan prints, not vanilla quarters.
- Beat-magnitude has decoupled from price reaction. The 79.5% beat on 13 May 2026 produced only a +3.5% same-week reaction; the 17.6% beat on 6 Feb 2026 produced +13.1% because it carried the buyback. The next "ordinary" beat is unlikely to clear a low-single-digit reaction unless something else changes on the print — guidance lift, machi-ka site, KPI surprise.
- Misses produce sharp moves only when they reset the plan. The May 2025 FY25 print missed Q4 EPS by 47% but the stock rallied +6.1% next day and +14.7% over five days because the new mid-term plan was the larger event. A pure operating miss without a planning catalyst is the highest-vulnerability tape configuration — and that is precisely the setup heading into Q1 FY3/2027 on 13 Aug 2026.
The live debate — what the market is watching now
The first three questions are testable inside the next six months. Q4 (positioning) is structural and matters at the margin. Q5 (CLSA) is an embedded sentiment trap — the valuation call has been correct, the direction call has been wrong, and an H1 FY27 KPI beat is what flips the consensus distribution. Q6 (machi-ka) is the durable upside pillar and is not a near-term catalyst — the first committed-site / IRR disclosure most plausibly lands with the next mid-term-plan refresh circa May 2028.
Ranked catalyst timeline — by decision value, not by date
This is the single required artifact of the tab. The rank below is by decision value to a PM underwriting the five-to-ten-year thesis. Dated commitments and event windows that introduce a raw filing fact are cited in the prose above the table; markers never sit inside a row. Spot reference: ¥3,871 / 19 Jun 2026.
The Q1 FY3/2027 print date (13 Aug 2026) and Ex-Dividend Date (29 Sep 2026) come from the staged earnings calendar (yfinance:3099.T). The Shinkong tranche-2 close on 1 April 2026 with a transfer gain of approximately ¥10B is from the FY3/2026 results subsequent-events disclosure [2]. The ¥30B / 18M-share buyback authorisation running through 8 Feb 2027 and tied to "earnings upside plus Shinkong cash inflow" is from the Q3 FY3/2026 web briefing Q&A [4]. FY3/2027 operating-profit guide of ¥81.5B and FY3/2028 Phase I anchor of ¥85B reaffirmed at the May 2026 web briefing [5]. Phase I cumulative shareholder return of ¥150B over FY3/2026-2028 at 70%+ total payout and DOE ≥5% from FY3/2028 are board-committed in the FY3/2026 tanshin [1]. The MI Card system change scheduled February 2027 is disclosed at the May 2026 web briefing [5]. The Annual General Meeting / Board changes (Hosoya / Makino re-appointed; two new directors including Kyoko Kawarabayashi and Yukari Suzuki) are scheduled for 22 June 2026 per the FY3/2026 results document [6].
What resolves the underwriting debate vs. what is information-only
The single most decision-relevant near-term event is #1 H1 FY3/2027 (12 Nov 2026). Q1 FY3/2027 (13 Aug 2026) is the highest-frequency catalyst but the lowest-resolution test — one quarter where the inbound base effect, the Shinkong gain in extraordinary income, and the early benefit of the FY26 SG&A discipline all collide. The buyback expiry (Feb 2027) is a sub-debate but a clean one. The two events that will determine whether the 5-to-10-year thesis is paid back — Phase II first machi-ka site and the cap-rate / IRR framing — sit beyond six months and are flagged for the watch-list, not for the next 90 days.
The next 90 days
Calendar quality is Medium. The 90-day window has one operating print (Q1 FY3/2027 on 13 Aug 2026) and one mechanical event (ex-div ~29 Sep 2026). The single highest-resolution event is the H1 print on ~12 November 2026 — just outside 90 days. The catalyst calendar is dense enough that a quiet 90 days is implausible, but the first event that actually closes a long-term-thesis debate sits at ~150 days.
What would change the view
Three observable signals would force the underwriting view to change inside the next six months. These are the events to mark in the dashboard.
The first three signals are observable inside the next six months. The fourth and fifth are continuous-watch and not predictable from the current information base. The PM's single most-decision-relevant flag for the next two prints is the structural-vs-cyclical separation in identified-customer sales — every other catalyst on this page either confirms or refines that read.
References
- Isetan Mitsukoshi Holdings — FY3/2026 Full-Year Results (Tanshin), FY3/2027 Consolidated Forecast (NI ¥61.5B -19.2% YoY; OP ¥81.5B); Phase I Shareholder Return Policy (70%+ payout; DOE ≥5% from FY3/2028); DPS ¥70 / FY27 plan ¥80 — p.2
- Isetan Mitsukoshi Holdings — FY3/2026 Full-Year Results (Tanshin), Subsequent Events: Shinkong Mitsukoshi (Taiwan) Equity-Stake Tranche-2 Transfer to Hsin Feng Capital Completed 1 April 2026; ~¥10B Transfer Gain; Post-Sale Stake 10% — p.22
- Isetan Mitsukoshi Holdings — Q3 FY3/2026 Earnings Web Briefing Q&A (6 Feb 2026), China/HK Customer Share 46%/7% (1H FY25) → 35%/9% (Oct–Dec 2025); ¥3B Sales / ¥0.5B OP Hit in 3Q; Q4 Overseas at 87% YoY — p.1
- Isetan Mitsukoshi Holdings — Q3 FY3/2026 Earnings Web Briefing Q&A (6 Feb 2026), ¥30B / 18M-Share Buyback Authorisation Rationale Tied to Earnings Upside + Related-Party Stock Sale Cash Inflow; Phase I ¥150B Shareholder Return / 70% Total Payout — p.2
- Isetan Mitsukoshi Holdings — Q4 FY3/2026 Earnings Web Briefing Q&A (13 May 2026), FY3/2027 OP Guide ¥81.5B; Phase I ¥85B FY3/2028 Target Reaffirmed; MI Card Scheme Change February 2027 (¥2B FY27 / Larger FY28+ Uplift) — p.2
- Isetan Mitsukoshi Holdings — FY3/2026 Full-Year Results (Tanshin), Board Changes Effective 22 June 2026 AGM: Hosoya (CEO) and Makino (CFO) Re-Appointed; New Directors Kyoko Kawarabayashi and Yukari Suzuki — p.23